MedTrace Logo

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2019-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy

Conditions

Interventions

BIOLOGICAL

XmAb5871

BIOLOGICAL

Placebo to match XmAb5871

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • ICON plc

    collaborator INDUSTRY

  • Xencor, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-16
Primary Completion
2018-07-17
Completion
2018-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02725515 on ClinicalTrials.gov